<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ophthalmology Product Guide &#187; Ozurdex</title>
	<atom:link href="http://www.ophthalmologyproductguide.com/blog/tag/ozurdex/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.ophthalmologyproductguide.com/blog</link>
	<description>A comprehensive guide to ophthalmology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:36:57 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Allergan receives approval for Ozurdex</title>
		<link>http://www.ophthalmologyproductguide.com/blog/2009/07/16/allergan-receives-approval-for-ozurdex/</link>
		<comments>http://www.ophthalmologyproductguide.com/blog/2009/07/16/allergan-receives-approval-for-ozurdex/#comments</comments>
		<pubDate>Thu, 16 Jul 2009 07:30:44 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[Macular degeneration]]></category>
		<category><![CDATA[Refractive Disorders]]></category>
		<category><![CDATA[Retina]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[corticosteroid]]></category>
		<category><![CDATA[dexamethasone]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[macular edema]]></category>
		<category><![CDATA[Ozurdex]]></category>

		<guid isPermaLink="false">http://www.ophthalmologyproductguide.com/blog/2009/07/16/allergan-receives-approval-for-ozurdex/</guid>
		<description><![CDATA[Multi-specialty healthcare company Allergan Inc announced that it has received approval from the FDA for Ozurdex 0.7 mg indicated for the treatment of the eye disease macular edema. Ozurdex is a first-of-its kind therapy dispensed by way of intravitreal injection delivering dexamethasone, a highly potent corticosteroid, through its proprietary and innovative Novadur solid polymer delivery [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.ophthalmologyproductguide.com/blog/wp-content/uploads/2009/07/ozurdex.png" align="left" height="88" width="200" vspace="5" hspace="5" />Multi-specialty healthcare company Allergan Inc announced that it has received approval from the FDA for Ozurdex 0.7 mg indicated for the treatment of the eye disease macular edema. Ozurdex is a first-of-its kind therapy dispensed by way of intravitreal injection delivering dexamethasone, a highly potent corticosteroid, through its proprietary and innovative Novadur solid polymer delivery system.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ophthalmologyproductguide.com/blog/2009/07/16/allergan-receives-approval-for-ozurdex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
